Quality Insights & Best Practices
Articles on regulated quality operations — written to support migration and validation conversations, not generic marketing. For legacy system replacement themes, see also legacy eQMS replacement.
Browse by Topic:
No matches found
Try a different search, or browse popular reads below.
Supplier quality management is one decision made repeatedly. What it has to produce, what spreadsheets and email cost, and what to demand from an eQMS.
Read full article
Part 11 Inspection Prep Checklist: What to Have Ready
Part 11 inspection prep, control by control: the artefact an investigator asks to see, what ready looks like, the usual gap, and who at the site owns it.
ICH Q9(R1): What Changed for Quality Risk Management, and What to Do About It
ICH Q9(R1) named subjectivity, made formality a spectrum and pulled supply risk into scope. A head of quality's guide to what changed and what to demand.
QMSR Transition Gap Assessment: How to Run One
How a device site scopes, runs, records and signs a QMSR gap assessment against ISO 13485:2016 as incorporated, and how the gaps flow into change control.
Multi-Tenant Audit Trails, Part 2: What Database-per-Tenant Changes
Part 1 asked whether your vendor's tenant boundary holds. Part 2 is the follow-up question: if the answer is database-per-tenant, what does that buy you?
What You Can and Cannot Automate in GxP Validation Evidence
FDA's CSA guidance widens how you may test. It does not endorse an unattended validation pipeline. Where the automation ceiling actually sits, and why.
OOS Investigation — What FDA Still Expects in 2026
Barr still rules retesting. FDA's OOS guidance got a Level 2 revision in 2022, not a rewrite. Phase I/II files, averaging, and CAPA linkage under inspection.
Choosing a GxP Cloud Region: What Data Residency Actually Locks In
"Which regions do you support?" is the wrong question. Region is chosen once, at provisioning — locking in latency, service availability and DR posture.
FDA Is Rewriting How You Respond to a 483. Are Your CAPAs Ready?
QMSR took effect February 2, 2026 and CP 7382.850 replaced QSIT. What to expect in post-QMSR 483 citations, and what your CAPA must produce in 15 days.
Why CDMO Quality Systems Break at the Seams — and What 'Tenant of One' Should Mean
CDMOs serve dozens of sponsors, but every sponsor audits the CDMO as an extension of their own facility. 'Tenant of one' is the architecture that resolves it.
The 6 Quality-System Gaps That Kill Your First IND
74% of FDA Complete Response Letters cite CMC or quality gaps. The six that stall a first IND are predictable — and cheapest to close before pre-IND.
GAMP 5 Second Edition and AI: What 'Category 5' Means When the Model Retrains Itself
GAMP 5 Category 5 assumed software was static at release. AI retrains itself. What Appendix D11 adds, and why validation evidence is a stream, not a binder.
The Purolea Warning Letter, Read as an Audit-Trail Spec
FDA's first cGMP warning letter to cite AI names two clauses and one accountability boundary. Read the clauses, not the coverage, and you get a record schema.
Per-Tenant Validation: How CDMOs Prove Sponsor Segregation
How CDMOs prove sponsor segregation under a supplier audit: the SQL query test, ICH Q10, EU GMP Chapter 7, and the eQMS records auditors demand.
If Your CAPAs Are Slow, Your QMS Architecture Is Wrong (Not Your Team)
Slow CAPAs get blamed on overworked QA, but the cycle-time data says otherwise: the wasted days sit at the seams between your eQMS modules, not your team.
QMSR Is Live — Here's the 12-Clause Map to Your eQMS
QMSR became effective February 2, 2026. The buttons in your eQMS didn't change — the evidence FDA wants behind them did. 12 ISO 13485:2016 clauses show where.
The Multi-Tenant SaaS Audit-Trail Problem No One's Writing About
Part 11 predates multi-tenant SaaS. Read modern data-integrity guidance against a shared eQMS and you find the audit trail leaks five layers deep.
Warning Letter Trends 2025: What Recurring Quality-System Breakdowns Reveal
FDA warning letter trends read from the FY 2024 and FY 2025 inspection data: which citations grew, what the letter asks for beyond the 483, and how to plan.
FDA Form 483 Examples: What Quality Teams Should Learn from Common Observations
FDA Form 483 examples read from the FY 2025 observation data: which 21 CFR sections recur for drugs and devices, what each asks for, and how to answer.
QMSR vs ISO 13485: What Actually Changes for Quality Systems
QMSR incorporates ISO 13485:2016, but a certificate isn't compliance. What FDA kept, what it added in §820.3, §820.10, §820.35 and §820.45, what it removed.
CSV vs CSA in Pharma: What Software Assurance Actually Means Under Inspection
CSV and CSA pursue the same confidence by different routes. FDA's final guidance: the four CSA steps, process risk, and the record an inspection asks for.
Connected Quality Records in Pharma: Why Silos Still Fail Under Inspection
Connected quality records help pharma teams defend deviations, CAPAs, changes, documents, and training as one evidence path under inspection.
Document Control in Pharma: Why Version History Still Fails
A revision log records what changed; document control has to prove what was in use, where, on a date. Where control breaks while the log stays clean.
Why Hybrid Paper-Digital Quality Systems Fail Inspections
Hybrid QMS setups fail when paper and digital records cannot be reconciled into one controlled, retrievable evidence chain.
Training Effectiveness in Pharma: Why Completion Is Not Enough
A green training matrix is a count. Effectiveness is whether the person who did the work was qualified on the revision in force that day.
QMS vs eQMS in Pharma: What Actually Changes
A QMS is the management system. An eQMS is software that may run it. What changes is whether CAPA, change and training stay on one path you can defend.
eQMS for Pharma Manufacturing: How to Evaluate Before You Buy
Buying an eQMS is a quality-system decision. Score the evidence chain, validation posture and inspection retrieval before you sit through demos.
Deviation, CAPA, and Change Control in Pharma: Why They Must Stay Linked
§211.192 asks for conclusions and follow-up, not a closed form. The five seams where the deviation→CAPA→change chain breaks, and what an investigator traces.
Why Audit Trails Fail Even in Digital Systems
An audit trail is a table that only records what it is pointed at. Where trails break after validation: off by default, no before-value, no review.
ALCOA+ in Practice: What Makes a Record Trustworthy
A changed value is three facts: who, when, what it said before. The nine ALCOA+ conditions, the clause behind each, where records break on real sites.
21 CFR Part 11: What Pharma Teams Actually Need to Know
Part 11 read from its scope clause: which records it reaches, what the 2003 guidance narrowed, and the five control points tested in practice.
Why Spreadsheets Fail in Regulated Quality Systems
A workbook has one modified-date and it belongs to the file, not to any cell. What Part 211, Part 11 and MHRA require of a spreadsheet holding the record.
Stay Updated on Quality & Compliance
Get practical updates, new resources, and rollout guidance tailored for regulated quality teams.